Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 15/20 | 0.66 |
| ▸ | NSD2 | O96028 | 5/20 | 0.51 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064028 | 1.00 | EHMT2 (0.66) | EHMT2NSD2EHMT1DNMT1SSTR5 | |
| SCHEMBL24844057 | 0.93 | EHMT2 (0.75) | EHMT2NSD2EHMT1CCR4 | |
| SCHEMBL30064011 | 0.93 | EHMT2 (0.75) | EHMT2NSD2EHMT1CCR4 | |
| SCHEMBL20745263 | 0.90 | EHMT2 (0.68) | EHMT2EHMT1DNMT1 | |
| SCHEMBL30064736 | 0.90 | EHMT2 (0.68) | EHMT2EHMT1DNMT1 | |
| SCHEMBL20745541 | 0.89 | EHMT2 (0.67) | EHMT2NSD2EHMT1SSTR5 | |
| SCHEMBL30064017 | 0.89 | EHMT2 (0.67) | EHMT2NSD2EHMT1SSTR5 | |
| SCHEMBL30063308 | 0.87 | EHMT2 (0.62) | EHMT2NSD2EHMT1DNMT1CCR4 | |
| SCHEMBL24843978 | 0.87 | EHMT2 (0.62) | EHMT2NSD2EHMT1DNMT1CCR4 | |
| SCHEMBL25489867 | 0.87 | EHMT2 (0.63) | EHMT2NSD2EHMT1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-3668863-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EHMT2 2/4885NSD2 133/4885EHMT1 1/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885NSD2 133/4885EHMT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.